Abstract
African-American subjects with interstitial lung disease are younger, less likely to be male and may have greater survival time than other racial groups, despite similar risk of respiratory hospitalisation, and GAP-ILD (gender-age-physiology-ILD) scores
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of Interest Disclosures: Drs. Adegunsoye, Chung JH, Montner, Lee, Bellam, Chung P, Biblowitz, along with Ms. Hsu, have nothing to disclose. Dr. Oldham has received speaking and advisory board fees from Genentech and Boehringer Ingelheim. Dr. Vij has received a grant from Genentech to study the genomics of autoimmune interstitial lung diseases. Dr. Noth has received honoraria for advisory boards with Boehringer Ingelheim, InterMune, Anthera within the last 12 months related to IPF. He has also received speaking honoraria from GSK and receives consulting fees for Immuneworks. He also has study contracts with the NIH, Stromedix, Sanofi, and BI for the conduct of clinical trials in IPF. Dr. Strek has received institutional funding for interstitial lung disease research from Boehringer-Ingelheim, Genentech, Gilead and MedImmune and has served on an advisory board for Boehringer-Ingelheim. Dr. Churpek is supported by a career development award from the National Heart, Lung, and Blood Institute (K08 HL121080), has received honoraria from Chest for invited speaking engagements and also has a patent pending (ARCD. P0535US.P2) for risk stratification algorithms for hospitalized patients.
Conflict of interest: Dr. Adegunsoye has nothing to disclose.
Conflict of interest: Dr. Oldham received speaking and advisory board fees from Genentech and Boehringer Ingelheim.
Conflict of interest: Dr. Bellam has nothing to disclose.
Conflict of interest: Dr. Chung has nothing to disclose.
Conflict of interest: Dr. Chung has nothing to disclose.
Conflict of interest: Dr. Biblowitz has nothing to disclose.
Conflict of interest: Dr. Montner has nothing to disclose.
Conflict of interest: Dr. Lee has nothing to disclose.
Conflict of interest: Ms. Hsu has nothing to disclose.
Conflict of interest: Dr. Husain has nothing to disclose.
Conflict of interest: Dr. Vij received a grant from Genentech to study the genomics of autoimmune interstitial lung diseases.
Conflict of interest: Dr. Mutlu has nothing to disclose.
Conflict of interest: Dr. Noth received honoraria for advisory boards with Boehringer Ingelheim, InterMune, Anthera within the last 12 months related to IPF. He has also received speaking honoraria from GSK and receives consulting fees for Immuneworks. He also has study contracts with the NIH, Stromedix, Sanofi, and BI for the conduct of clinical trials in IPF. .
Conflict of interest: Dr. Churpek is supported by a career development award from the National Heart, Lung, and Blood Institute (K08 HL121080), has received honoraria from Chest for invited speaking engagements and also has a patent pending (ARCD. P0535US.P2) for risk stratification algorithms for hospitalized patients.
Conflict of interest: Dr. Strek received institutional funding for interstitial lung disease research from Genentech, Gilead and MedImmune and she serves on a data monitoring committee for Boehringer Ingelheim.
This is a PDF-only article. Please click on the PDF link above to read it.
- Copyright ©ERS 2018